A Study of Amolimogene (ZYC101a) in Patients With High Grade Cervical Intraepithelial Lesions of the Uterine Cervix

Eisai Inc.251 enrolled

Overview

The purpose of this study is to evaluate the efficacy and safety of amolimogene, in the treatment of patients with high-grade cervical intraepithelial lesions of the uterine cervix.

This is a double-blind study, so neither the patient not the doctor will know which treatment has been assigned.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

TRIPLE

Enrollment

251

Conditions

Uterine Cervical Dysplasia

Interventions

AmolimogeneDRUG

1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.

AmolimogeneDRUG

3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.

PlaceboOTHER

Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.

Eligibility

Sex: FEMALEMin age: 13 YearsMax age: 25 Years

Medical Language ↔ Plain English

Inclusion Criteria: To be considered for enrollment, patients must: 1. Have an abnormal Pap smear (atypical squamous cells of undetermined significance \[ASCUS\], atypical squamous cells, cannot exclude high grade \[ASC-H\], low grade squamous intraepithelial lesion \[LSIL\], high grade squamous intraepithelial lesion \[HSIL\]) result within 6 months of screening visit. 2. Have a colposcopically visible lesion suspected to be high-grade that does not involve more than 75% of the cervix. 3. Have a CIN 2/3 consensus pathology diagnosis on tissue taken from a colposcopically-directed punch biopsy. 4. Not have evidence of cervical carcinoma on Pap smear or biopsy and not have a positive endocervical curettage. 5. Not have atypical endometrial cells or glandular-cell atypia on Pap smear or biopsy. 6. Have colposcopic visualization of entire squamocolumnar junction and of the entire lesion (i.e. cannot extend into canal). 7. Not have concomitant cancer, history of malignancies, including carcinoma of the cervix, except for non-melanoma skin cancer. 8. Be willing to sign an Institutional Review Board (IRB) approved informed consent. Minors must have the consent of a parent or legal guardian as required by local laws and regulations. 9. Agree to use 2 acceptable forms of contraception (e.g., double-method including at least one barrier and one hormonal method). 10. Be capable of complying with the protocol. 11. Not have other illnesses that would put the patient at undue risk for participation in the trial or would interfere with the required clinical observations. 12. Not have abnormalities of hematological, renal, or hepatic function as determined by clinical laboratory testing. 13. Not have immunologic disorder such as immunodeficiency, lupus, or other chronic auto-immune disease. 14. Not have an active systemic infection requiring treatment. 15. Not have ongoing systemic chronic steroid therapy or immunosuppressive medication (inhalers used for treating asthma and topical steroids are permitted). 16. Not be positive for HIV antibody. 17. Not be pregnant or lactating. 18. Not plan to use a cervical cap or diaphragm during the study. 19. Not have been treated with any investigational agent within 30 days prior to randomization in this trial. 20. Not have had prior gene therapy. 21. Not have had an excisional or ablative procedure performed on the cervix within one year of enrollment. 22. Be willing to consent to an excisional procedure, such as LEEP or cold-knife cone procedure, if indicated. Please note: There may be additional inclusion/exclusion criteria. The study center will determine if patients meet all of the criteria. If patients do not qualify for the trial, study personnel will explain the reasons. If patients do qualify, study personnel will explain the trial in detail using an IRB-approved informed consent, and answer any questions. Patients can then decide if they wish to participate.

Locations (26)

Outcomes

Primary Outcomes

Cervical intraepithelial neoplasia (CIN) 2/3 resolution, defined as the histological evaluation of cervical tissue (presence or absence of CIN 2/3 as determined by pathology consensus diagnosis) at the End of Observation (EOO) period.